MINIALO-VELCADE2005: A Phase II National, Open-Label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning.

Trial Profile

MINIALO-VELCADE2005: A Phase II National, Open-Label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2014

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Fludarabine; Melphalan
  • Indications Bone marrow transplant rejection; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 27 Feb 2013 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 19 May 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top